Trial Profile
An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Avitinib (Primary) ; Crizotinib (Primary) ; Ensartinib (Primary) ; Tucidinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TRUMP
- 06 Feb 2020 Status changed from not yet recruiting to recruiting.
- 05 Jul 2018 New trial record